Jeffrey S. Hackman - 14 Feb 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc.

Role
Chairman, President, and Chief Executive Officer., Director
Signature
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
Issuer symbol
CMRA on OTC
Transactions as of
14 Feb 2023
Net transactions value
$0
Form type
4
Filing time
16 Feb 2023, 17:20:01 UTC
Previous filing
12 Sep 2022
Next filing
28 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMRA Stock Option (Right to Purchase) Award $0 +100,000 $0.000000 100,000 14 Feb 2023 Common Stock 100,000 $1.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the stock option vest on February 14, 2024, with the remaining shares vesting on a monthly basis on the 14th day of each month thereafter, in each case, subject to continuous service to the issuer, such that the option shall be fully vested on February 14, 2027.

Remarks:

Chairman, President, and Chief Executive Officer.